Computational modeling of microfluidic data provides high-throughput affinity estimates for monoclonal antibodies

[1]  J. Juneja,et al.  Application of the Gyrolab microfluidic platform to measure picomolar affinity of a PD-L1-binding Adnectin™ radioligand for positron emission tomography. , 2020, BioTechniques.

[2]  J. Mascola,et al.  Monoclonal Antibodies for Prevention and Treatment of COVID-19. , 2020, JAMA.

[3]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[4]  J. Hood,et al.  European Bioanalysis Forum recommendation on singlicate analysis for ligand binding assays: time for a new mindset. , 2020, Bioanalysis.

[5]  P. Mcgonigle,et al.  The pharmacology and therapeutic applications of monoclonal antibodies , 2019, Pharmacology research & perspectives.

[6]  Paramita Sarkar,et al.  Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance. , 2019, Trends in microbiology.

[7]  Y. Wen,et al.  From therapeutic antibodies to immune complex vaccines , 2019, npj Vaccines.

[8]  R. Rappuoli,et al.  Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes , 2018, Scientific Reports.

[9]  G. Alter,et al.  Systems serology: profiling vaccine induced humoral immunity against HIV , 2017, Retrovirology.

[10]  R. A. van den Berg,et al.  Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans , 2017, Front. Immunol..

[11]  J. Andersen,et al.  Antibody-antigen kinetics constrain intracellular humoral immunity , 2016, Scientific Reports.

[12]  I. Carletti,et al.  Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. , 2016, Clinical immunology.

[13]  P. Klasse.  How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses , 2016, Expert review of vaccines.

[14]  I. Carletti,et al.  Impact of adjuvants on CD 4 + T cell and B cell responses to a protein antigen vaccine : Results from a phase II , randomized , multicenter trial , 2016 .

[15]  John P. Moore,et al.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure? , 2015, Journal of Virology.

[16]  Yingda Xu,et al.  High throughput solution-based measurement of antibody-antigen affinity and epitope binning , 2013, mAbs.

[17]  Hossein Salimi-Moosavi,et al.  Rapid affinity measurement of protein-protein interactions in a microfluidic platform. , 2012, Analytical biochemistry.

[18]  R. Brink,et al.  Affinity‐based selection and the germinal center response , 2012, Immunological reviews.

[19]  A. Rajpal,et al.  Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions , 2012, PloS one.

[20]  Paul Leonard,et al.  Measuring protein-protein interactions using Biacore. , 2011, Methods in molecular biology.

[21]  Johanna R Mora,et al.  Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective. , 2010, Bioanalysis.

[22]  A. Casadevall,et al.  Monoclonal antibody-based therapies for microbial diseases , 2009, Vaccine.

[23]  J. Bruno,et al.  Using Biacore to Measure the Binding Kinetics of an Antibody‐Antigen Interaction , 2006, Current protocols in protein science.

[24]  Sophia Hober,et al.  Microfluidic analysis of antibody specificity in a compact disk format. , 2006, Journal of proteome research.

[25]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[26]  R. Darling,et al.  Kinetic exclusion assay technology: characterization of molecular interactions. , 2004, Assay and drug development technologies.

[27]  David G Myszka,et al.  Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. , 2004, Analytical biochemistry.

[28]  S A Bobrovnik,et al.  Determination of antibody affinity by ELISA. Theory. , 2003, Journal of biochemical and biophysical methods.

[29]  J. L. Sebaugh,et al.  Defining the linear portion of a sigmoid‐shaped curve: bend points , 2003 .

[30]  R. Karlsson.  Affinity analysis of non‐steady‐state data obtained under mass transport limited conditions using BIAcore technology , 1999, Journal of Molecular Recognition.

[31]  R. Blake,et al.  Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. , 1999, Analytical biochemistry.

[32]  A. Kortt,et al.  Influence of mass transfer and surface ligand heterogeneity on quantitative BIAcoreTM binding data. Analysis of the interaction of NC10 Fab with an anti‐idiotype Fab′ , 1997, Journal of molecular recognition : JMR.

[33]  J. E. Moyal.  XXX. Theory of ionization fluctuations , 1955 .

[34]  Lev Davidovich Landau,et al.  On the energy loss of fast particles by ionization , 1944 .